Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8710294 | 0.98 | CA1 (0.35) | CA1CA2 | |
| Trifluoroacetic Acid SCHEMBL18953889 | 0.86 | DPP8 (0.32) | CA1 | |
| SCHEMBL5540 | 0.81 | CA1 (0.39) | CA1CA2PMP22 | |
| SCHEMBL25390760 | 0.80 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL10500021 | 0.80 | CA1 (0.37) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL3354866 | 0.79 | CA1 (0.38) | CA1CA2PMP22 | |
| SCHEMBL20744255 | 0.78 | — | — | |
| SCHEMBL14167181 | 0.78 | KDM4E (0.33) | PMP22 | |
| SCHEMBL11021093 | 0.78 | NOS2 (0.31) | — | |
| SCHEMBL14248747 | 0.78 | KDM4E (0.33) | PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | claimed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | claimed |
| CN-110088087-A | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | 东亚ST株式会社 | 2019-08-02 | — | — | CN | claimed |
| WO-2019038362-A1 | ANTIBACTERIAL PYRROLOIMIDAZOLONES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-28 | — | — | WO | claimed |
| CN-105829288-B | Antibacterial 1H- indazole and 1H- indole derivatives | 爱杜西亚药品有限公司 | 2019-01-15 | — | — | CN | claimed |
| EP-3344630-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-11 | — | — | EP | claimed |
| EP-3341378-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-04 | — | — | EP | claimed |
| EP-3221300-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-09-27 | — | — | EP | claimed |
| WO-2017037221-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | claimed |
| WO-2017036968-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | claimed |
| WO-2016079688-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-26 | — | — | WO | claimed |
| EP-2847168-A1 | ANTIBACTERIAL AGENTS | Achaogen, Inc. (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2694488-A1 | ISOXAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2013170165-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2013-11-14 | — | — | WO | claimed |
| WO-2012137094-A1 | ISOXAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-10-11 | — | — | WO | claimed |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | ELAN PHARMACEUTICALS, INC. | 2008-07-03 | — | — | US | claimed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996028464-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | CA1 3598/4885CA2 3019/4885PMP22 2681/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | CA1 3598/4885CA2 3019/4885PMP22 2681/4885 |
| US-20080161325-A1 | e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome | BACE1, APP, BACE2 | CA1 1011/4885CA2 2723/4885PMP22 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.